SFDA Updates Regulatory Framework for Drug Approval (Version 6.4)
The Saudi Food and Drug Authority (SFDA) has issued Version 6.4 of the Regulatory Framework for Drugs Approval, marking another step forward in modernizing the drug registration system in Saudi Arabia. This update, finalized in June 2024 and implemented from October 2023, introduces important refinements to submission, assessment, and approval processes, alongside the addition of new regulatory pathways to accelerate patient access to innovative medicines.
Key Updates in Version 6.4
- New Marketing Authorization Applications (MAA)
- Online submission via SDR system is mandatory, supported by technical and business validation.
- Applicants must respond to electronic inquiries within specified timelines to avoid rejection.
- Performance targets are clearly defined across regular, priority, and reliance pathways, enhancing predictability.
- Breakthrough Medicine Designation (New Addition)
- A Breakthrough Medicine Program has been introduced to fast-track the review of innovative drugs that address serious or life-threatening conditions with unmet medical needs. This program fosters early dialogue between drug developers and SFDA, aiming to accelerate access without compromising safety and efficacy.
- Variation of Marketing Authorization
- Minor variations (Type IA/IB) – simplified processes with clear “Do and Tell” or “Tell, Wait and Do” procedures.
- Major variations (Type II) – requiring prior SFDA approval before implementation.
- Defined rejection cases for incomplete or incorrect submissions.
- Updated performance targets for each variation type.
- Renewal of Marketing Authorization
- Online renewal submission with clear validation steps.
- Defined timelines for pricing review and product licensing.
- Appeal processes available within 60 days of a final decision.
Why This Matters for Industry & Regulators
- Streamlined submission processes through online systems and validation steps.
- Faster review pathways for priority, verification, and breakthrough medicines.
- Clearer rules on variations and renewals, reducing uncertainty and delays.
- Alignment with international best practices, ensuring Saudi Arabia remains a competitive hub for pharmaceutical innovation.
Conclusion
The Regulatory Framework for Drugs Approval (V6.4) represents a significant advancement in SFDA’s regulatory modernization. By combining structured procedures with innovative pathways like the Breakthrough Medicine Program, the SFDA continues to balance timely patient access with robust regulatory oversight.
